(Ian Snug/ Nursing Notes) — Inclisiran, a bi-annual injection to lower cholesterol, is set to be studied in UK patients as part of a large-scale NHS clinical trial expected to start later this year.
In a world-first, the drug is expected to be available through a population-level agreement – pioneering a game-changing approach to reducing the risk of heart disease.
According to the Department of Health and Social Care (DHSC), early clinical trial results suggest that if Inclisiran is given to 300,000 patients annually, it could help prevent 55,000 heart attacks and strokes, and has the potential of saving 30,000 lives in the next 10 years.
Heart disease is the world’s biggest killer and the second biggest cause of death in the UK and 2 and a half million patients currently relying on statins to lower their cholesterol.
Recent trials have shown Inclisiran can halve bad cholesterol in just 2 weeks. (…)